Company news

Neurotech International Ltd. news in 2024

Neurotech International Ltd.'s news releases, calls and decks from 2024, newest first.

View company

Neurotech Receives US ODD in Rett Syndrome

November 25, 2024

NTI Receives Ethics Approval to Commence Human PK Study

November 24, 2024

Positive Genomic Effects of NTI164 in PANDAS/PANS Patients

November 14, 2024

Neurotech Appoints Dr Anthony Filippis as MD/CEO

November 10, 2024

US FDA Response to Orphan Drug Request in PANDAS/PANS

October 3, 2024

NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children

September 8, 2024

Neurotech Global Partnering and Registration Strategy

August 11, 2024

Further Significant Improvement in Rett Syndrome Patients

July 30, 2024

Phase II/III autism trial shows further benefits

July 17, 2024

Significant improvement in Autism patients at 12 weeks

July 9, 2024

Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment

June 16, 2024

Further clinical benefit at 52 weeks in PANDAS/PANS patients

June 5, 2024

Rett Syndrome Phase I/II trial shows significant benefits

May 5, 2024

Neurotech Completes $10 Million Capital Raise

April 17, 2024

Positive Top-Line Rett Syndrome Clinical Trial Results

April 17, 2024

Phase II/III ASD Trial Successfully Meets Primary Endpoint

April 17, 2024

Last Patient Completes Treatment in NTIASD2 Clinical Trial

April 9, 2024

Rett Syndrome Patients to Receive NTI164 for 52 Weeks

March 12, 2024

PANDAS/PANS Patients Show Continued Clinical Improvement

February 20, 2024

Neurotech Receives Additional HREC Approval in Autism

February 12, 2024

NTI Receives HREC Approval for Cerebral Palsy Trial

January 28, 2024

Decks in 2024